NASDAQ: EVFM Will Earn 1.73 Million In Sales, As Per Stock Market Analysts


Evofem Biosciences Inc (NASDAQ: EVFM) has been issued a sales prediction of $1.73 million for this quarter by three stock market analysts. The equities market analysts also said that the company’s highest sales will total $2.95 million and the lowest estimate will be $500,000.00. 

As of now, Evofem Biosciences Inc is scheduled to announce its quarterly earnings on 4th November during the Wednesday report. 

As per Zach Investment Research, the company will bring in a yearly sale of $7.83 million for this FY. The estimates range between $3.10 million and $16.31 million. For 2021, analysts have predicted that the company will bring in $58.10 million. The estimates will range between $34.88 million and $88.93 million. 

Here’s How Brokerages Have Reacted To NASDAQ: EVFM 

ON 20th August, during The Thursday report, Stanley started covering NASDAQ: EVFM shares. Stanley also set its price target at $3.00 and rated Evofem Biosciences an “equal weight.” Similarly, Stifel Nicolaus covered Evofem Biosciences shares on 1st October during a Thursday report. Stifel Nicolaus also set its target price at $5.00 and issued a rating of “buy.” Zachs Investment Research increased its NASDAQ: EVFM rating of “Hold” to a rating of “sell” during a Tuesday report. Oppenheimer also increased its Evofem Biosciences target price to $25.00 from $18.00. On 10th August, during a Monday report, Oppenheimer also gave Evofem Biosciences a rating of “outperform.” Last but not the least, BidaskClub also increased it’s rating of “sell” to a rating of “strong sell” on 18th August during a Tuesday report. 

Out if the three stock market analysts, one gave Evofem Biosciences a rating of “sell” and two stock market analysts issued a rating of “hold” and seven issued a rating of “buy.” Currently, NASDAQ: EVFM holds an average “Buy” Rating and the consensus estimate target price is $8.94. 

Evofem Biosciences Inc last released its earnings report on 4th August drying a Tuesday report. As per reports, it’s earning per share is $0.91 for this quarter. 

Which Stock Market Investors Increased Or Reduced Their Evofem Biosciences Inc Stakes?

Bank of America Corp DE increased its NASDAQ: EVFM shares by 48 percent. It now owns an estimate of $35,000, which comes from 12,065 Evofem shares. Geode Capital Management LLC increased its NASDAQ: EVFM shares by 1.7 percent.  It currently owns an estimate of $1,410,000, which comes from 265,176 Evofem shares. Point72 Hong Kong Ltd recently purchased Evofem Biosciences Inc shares worth $25,000. Personal CFO Solutions LLC also purchased Evofem stakes worth $36,000. 

On Friday, Evofem Biosciences Inc stock started at $2.90. NASDAQ: EVFM market capitalization currently stands at $235.71 million.